HSPB11

Across TCGA pan-cancer cohorts, HSPB11 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated HSPB11 data layer compared with 22 for mass-spec protein and 2 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher HSPB11 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated HSPB11 expression acts as an unfavorable survival marker, although some lineages such as LSCC show a favorable association.

PDAC, LUAD, and LSCC are the cancer types where HSPB11 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	OS	Quartile	II,III,IV	0.251	0.732	<.001	38	view →
LUAD	OS	Quartile	All	0.907	1.000	.013	5	view →
LSCC	DFS	Tertile	All	0.866	0.339	.033	3	view →
GBM	OS	Tertile	All	0.704	0.891	.022	2	view →
CCRCC	DFS	Tertile	III,IV	0.425	0.743	.049	1	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

HSPB11–PDAC (OS)

Open the PDAC breakdown →